Q2 FY2026 EarningsQ2 FY2026 results significantly exceeded top-line consensus with revenue of $0.76M vs. $0.25M expected, primarily driven by license revenue. The GAAP net loss of $50.2M was deeper than the anticipated $45.3M due to accelerated R&D investment in late-stage clinical trials. However, the company maintains a robust liquidity position with $1.2B in cash, providing an operational runway into 2030, supported by positive Phase 3 interim data in CIDP.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Dianthus Therapeutics(DNTH) the Revenue is 761 K (+294.3%), Beat estimate;the EBIT is -61.48 M (-76.03%), Miss estimate;the EPS is -0.9 (-2.27%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B294.30%
0.00B28.89%
+0.00B265.41%
EBITMiss expectations
-0.06B76.03%
-0.05B48.65%
-0.01B27.38%
EPSMiss expectations
-0.92.27%
-0.84753.69%
-0.05255.96%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf